WORKSHOP: Partnering for rare disease outcomes - why AI is not enough
Information
NOTE: YOU NEED TO REGISTER (BLUE BUTTON)
While AI is seen as a key factor in patient cohort identification, there remain many barriers to successful execution. These exercises should not simply do the same as previous practice, just faster, better, cheaper, because patients will still remain undiagnosed.
What we will be discussing with other partners in the rare disease and personalised medicines arena, is how we can construct a new way of working that does not solely focus on AI and digital technology, but drives toward greater value across stakeholders: patients, patient groups, healthcare professionals, payers and of course for companies developing and commercialising medicines for smaller populations.
We will share a vision of innovative service delivery and then in the panel session, we will discuss some of the barriers and enablers to change the way we do business and create a more inclusive approach to deliver a future vision of healthcare.
These are pragmatic insights based on our joint experience that we wish to share with the audience so that you may put together smarter programmes of work across your internal departments for better outcomes.
Agenda:
10:30 CET – Welcoming remarks and introductions by Christopher Rudolf, Volv
10:40 CET – How does the Xperiome patient-powered platform personalize the patient’s journey? By Julie Walters, Raremark
11:10 CET – Use of novel AI/ML tools to support patient identification; perspectives from the Syneos Health Rare Disease Consortium by Ray Huml, Syneos Health
11:40 CET – Short break
11:45 CET – How does AI play a piece in this when put together? By Christopher Rudolf, Volv
12:00 – 13:00 CET: Interactive panel discussion with all speakers and LIVE Q&As
Christopher Rudolf, Volv
Alex Garner, Raremark
Ray Huml, Syneos Health
Ron Herings, The Pharmo Institute
13:00 CET Workshop finishes, the next will start 13:00 CET on OMPs.
